wvgazettemail.com

Harbour BioMed Receives China NMPA Approval of Batoclimab Injection (Subcutaneous Injection) for the Treatment of Generalized Myasthenia Gravis

Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of ...

ProBio Successfully Completes NMPA Pre-Approval Inspection for Biologics Manufacturing Facility in Nanjing, China

ProBio Inc., a global contract research, development and manufacturing organization (CRDMO), today announced the successful ...
RTTNews

NMPA Approves Harbour BioMed's Batoclimab SC For Generalised Myasthenia Gravis

Batoclimab is a fully human monoclonal antibody targeting the neonatal Fc receptor (FcRn). HanAll Biopharma Co., Ltd. originally developed Batoclimab and licensed it to Harbour BioMed in 2017 under a ...
RTTNews

Galderma Expands Relfydess Reach With China Approval For Frown Lines

Galderma ( GDERF) announced that China's National Medical Products Administration (NMPA) has approved Relfydess (relabotulinumtoxinA) for the temporary improvement of moderate-to-severe glabellar ...
Yahoo

China’s NMPA approves Sanofi’s rare haematologic disease treatments

Add Yahoo as a preferred source to see more of our stories on Google. The approvals mark the fourth and fifth clearances for Sanofi in the country in 2025. Credit: sylv1rob1/Shutterstock.com. China's ...
Morningstar%2c Inc.

China NMPA Grants IND Clearance to Adcentrx Therapeutics' ADRX-0405 STEAP1 ADC for the Treatment of Late-Stage Solid Tumors, Including Prostate Cancer

SAN DIEGO and SHANGHAI, June 8, 2026 /PRNewswire/ -- Adcentrx Therapeutics ("Adcentrx"), a clinical-stage biotechnology company advancing Antibody-Drug Conjugate (ADC) therapies for cancer treatment ...

China’s NMPA clears Foresee’s Camcevi 42 mg for prostate cancer

GenSci holds exclusive Chinese rights to Camcevi, covering central precocious puberty, premenopausal breast cancer, and ...
StreetInsider.com

Galderma’s Relfydess™ (relabotulinumtoxinA) Receives Approval in China for Frown Lines

The Chinese National Medical Products Administration (NMPA) has approved Relfydess, the first and only ready-to-use liquid neuromodulator designed with PEARL Technology, for the temporary improvement ...
The Mac Observer

Apple Watch sleep apnea notifications reach China mainland after NMPA approval

Apple Watch sleep apnea notifications launched in China mainland on October 14, 2026 after NMPA approval. See the supported ...
Nasdaq

Innovent and AnHeart Therapeutics Announce the NMPA of China Has Accepted Second NDA for Taletrectinib for First-Line Treatment of ROS1-Positive Lung Cancer

More than one million people globally are diagnosed with NSCLC annually, the most common form of lung cancer. It is estimated that approximately 3% of people with NSCLC in China are ROS1-positive.
BioSpectrum Asia

Foresee Pharma announces China NMPA approval of CAMCEVI® 42 mg for treatment of advanced prostate cancer

In addition to the NMPA's approval of CAMCEVI ® 42 mg for advanced prostate cancer described above, GenSci submitted a ...
Business Wire

China NMPA Approves Promega MSI Detection Kit as Companion Diagnostic for KEYTRUDA®

MADISON, Wis.--(BUSINESS WIRE)--The National Medical Products Administration (NMPA) has approved the OncoMate ® Microsatellite Instability (MSI) Detection Kit as a Class III in vitro diagnostic ...